The Latin America, Middle East and Africa Opioid Use Disorder (OUD) Market would witness market growth of 13.0% CAGR during the forecast period (2023-2030).
Medicare and all state Medicaid programs cover the treatment services offered by opioid treatment programs (OTPs). State Medicaid programs frequently pay for OTP services in daily or weekly bundles that include methadone doses, toxicological testing, nurse services, and counselling, using the code H0020. About 40% of all non-elderly people with opioid use disorder (OUD) are covered by Medicaid. The opioid use disorder market is expected to grow as a result of these treatment initiatives.
The Middle East and North Africa (MENA) are severely affected by the global public health problem known as opioid use disorder (OUD). As many as 12 Arab nations have shown significant opioid use rates, with Bahrain and Kuwait showing particularly high rates. The government and culture both have an impact on the complex opioid use in the ME. Opioid consumption is lower in oil-rich countries like Kuwait, Bahrain, Saudi Arabia, the United Arab Emirates, and Qatar. Iran stands out for having a high opioid usage rate.
The "opioid crisis" that other parts of the regional are going through could make Latin American countries' inadequate pain treatment worse. Regulating organizations in the area have already expressed alarm about it. To create a position paper on appropriate opioid usage in chronic pain, the Latin American Federation of IASP Chapters (FEDELAT) gathered a team of regional experts in So Paulo, Brazil. The group's research of the needs and unique characteristics of the area forms the basis for all recommendations. These advancements may help to improve laws and pain treatment, as well as to stop the abuse and misuse of these drugs. All these elements are estimated ort support the growth of the regional market.
The Brazil market dominated the LAMEA Opioid Use Disorder (OUD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $114.4 million by 2030. The Argentina market is anticipated to grow at a CAGR of 13.6% during (2023 - 2030). Additionally, The UAE market would exhibit a CAGR of 12.7% during (2023 - 2030).
Based on Drug Class, the market is segmented into Buprenorphine, Methadone and Naltrexone. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Opioid Use Disorder (OUD) Market is Projected to reach USD 6.4 Billion by 2030, at a CAGR of 9.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC , and Viatris, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Class
- Buprenorphine
- Methadone
- Naltrexone
By Route of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Indivior PLC (Reckitt Benckiser Group plc)
- Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
- Orexo AB (Orexo US, Inc.)
- Alkermes PLC
- Titan Pharmaceuticals, Inc.
- Camurus AB
- AstraZeneca PLC
- Hikma Pharmaceuticals PLC
- Mallinckrodt PLC
- Viatris, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Opioid Use Disorder (OUD) Market, by Drug Class
1.4.2 LAMEA Opioid Use Disorder (OUD) Market, by Route of Administration
1.4.3 LAMEA Opioid Use Disorder (OUD) Market, by Distribution Channel
1.4.4 LAMEA Opioid Use Disorder (OUD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Opioid Use Disorder (OUD) Market
Chapter 4. LAMEA Opioid Use Disorder (OUD) Market by Drug Class
4.1 LAMEA Buprenorphine Market by Country
4.2 LAMEA Methadone Market by Country
4.3 LAMEA Naltrexone Market by Country
Chapter 5. LAMEA Opioid Use Disorder (OUD) Market by Route of Administration
5.1 LAMEA Parenteral Market by Country
5.2 LAMEA Oral Market by Country
Chapter 6. LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel
6.1 LAMEA Hospital Pharmacies Market by Country
6.2 LAMEA Retail Pharmacies & Stores Market by Country
6.3 LAMEA Online Pharmacies Market by Country
Chapter 7. LAMEA Opioid Use Disorder (OUD) Market by Country
7.1 Brazil Opioid Use Disorder (OUD) Market
7.1.1 Brazil Opioid Use Disorder (OUD) Market by Drug Class
7.1.2 Brazil Opioid Use Disorder (OUD) Market by Route of Administration
7.1.3 Brazil Opioid Use Disorder (OUD) Market by Distribution Channel
7.2 Argentina Opioid Use Disorder (OUD) Market
7.2.1 Argentina Opioid Use Disorder (OUD) Market by Drug Class
7.2.2 Argentina Opioid Use Disorder (OUD) Market by Route of Administration
7.2.3 Argentina Opioid Use Disorder (OUD) Market by Distribution Channel
7.3 UAE Opioid Use Disorder (OUD) Market
7.3.1 UAE Opioid Use Disorder (OUD) Market by Drug Class
7.3.2 UAE Opioid Use Disorder (OUD) Market by Route of Administration
7.3.3 UAE Opioid Use Disorder (OUD) Market by Distribution Channel
7.4 Saudi Arabia Opioid Use Disorder (OUD) Market
7.4.1 Saudi Arabia Opioid Use Disorder (OUD) Market by Drug Class
7.4.2 Saudi Arabia Opioid Use Disorder (OUD) Market by Route of Administration
7.4.3 Saudi Arabia Opioid Use Disorder (OUD) Market by Distribution Channel
7.5 South Africa Opioid Use Disorder (OUD) Market
7.5.1 South Africa Opioid Use Disorder (OUD) Market by Drug Class
7.5.2 South Africa Opioid Use Disorder (OUD) Market by Route of Administration
7.5.3 South Africa Opioid Use Disorder (OUD) Market by Distribution Channel
7.6 Nigeria Opioid Use Disorder (OUD) Market
7.6.1 Nigeria Opioid Use Disorder (OUD) Market by Drug Class
7.6.2 Nigeria Opioid Use Disorder (OUD) Market by Route of Administration
7.6.3 Nigeria Opioid Use Disorder (OUD) Market by Distribution Channel
7.7 Rest of LAMEA Opioid Use Disorder (OUD) Market
7.7.1 Rest of LAMEA Opioid Use Disorder (OUD) Market by Drug Class
7.7.2 Rest of LAMEA Opioid Use Disorder (OUD) Market by Route of Administration
7.7.3 Rest of LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Indivior PLC (Reckitt Benckiser Group plc)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Product and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.3 Orexo AB (Orexo US, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Alkermes PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.5 Titan Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Trials and Approvals:
8.6 Camurus AB
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Trials and Approvals:
8.7 AstraZeneca PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.8 Hikma Pharmaceuticals PLC
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Product Launches and Product Expansions:
8.9 Mallinckrodt PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Viatris, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental Analysis
8.10.4 Research & Development Expense
TABLE 1 LAMEA Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 3 LAMEA Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 4 LAMEA Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 5 LAMEA Buprenorphine Market by Country, 2019 - 2022, USD Million
TABLE 6 LAMEA Buprenorphine Market by Country, 2023 - 2030, USD Million
TABLE 7 LAMEA Methadone Market by Country, 2019 - 2022, USD Million
TABLE 8 LAMEA Methadone Market by Country, 2023 - 2030, USD Million
TABLE 9 LAMEA Naltrexone Market by Country, 2019 - 2022, USD Million
TABLE 10 LAMEA Naltrexone Market by Country, 2023 - 2030, USD Million
TABLE 11 LAMEA Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 12 LAMEA Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 13 LAMEA Parenteral Market by Country, 2019 - 2022, USD Million
TABLE 14 LAMEA Parenteral Market by Country, 2023 - 2030, USD Million
TABLE 15 LAMEA Oral Market by Country, 2019 - 2022, USD Million
TABLE 16 LAMEA Oral Market by Country, 2023 - 2030, USD Million
TABLE 17 LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 18 LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 19 LAMEA Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 20 LAMEA Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 21 LAMEA Retail Pharmacies & Stores Market by Country, 2019 - 2022, USD Million
TABLE 22 LAMEA Retail Pharmacies & Stores Market by Country, 2023 - 2030, USD Million
TABLE 23 LAMEA Online Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 24 LAMEA Online Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 25 LAMEA Opioid Use Disorder (OUD) Market by Country, 2019 - 2022, USD Million
TABLE 26 LAMEA Opioid Use Disorder (OUD) Market by Country, 2023 - 2030, USD Million
TABLE 27 Brazil Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 28 Brazil Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 29 Brazil Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 30 Brazil Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 31 Brazil Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 32 Brazil Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 33 Brazil Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 34 Brazil Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 35 Argentina Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 36 Argentina Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 37 Argentina Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 38 Argentina Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 39 Argentina Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 40 Argentina Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 41 Argentina Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 Argentina Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 UAE Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 44 UAE Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 45 UAE Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 46 UAE Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 47 UAE Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 48 UAE Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 49 UAE Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 UAE Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 Saudi Arabia Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 52 Saudi Arabia Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 53 Saudi Arabia Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 54 Saudi Arabia Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 55 Saudi Arabia Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 56 Saudi Arabia Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 57 Saudi Arabia Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 Saudi Arabia Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 South Africa Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 60 South Africa Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 61 South Africa Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 62 South Africa Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 63 South Africa Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 64 South Africa Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 65 South Africa Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 South Africa Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 Nigeria Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 68 Nigeria Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 69 Nigeria Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 70 Nigeria Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 71 Nigeria Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 72 Nigeria Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 73 Nigeria Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 74 Nigeria Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 75 Rest of LAMEA Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 76 Rest of LAMEA Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 77 Rest of LAMEA Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 78 Rest of LAMEA Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 79 Rest of LAMEA Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 80 Rest of LAMEA Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 81 Rest of LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 82 Rest of LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 83 Key Information – Indivior PLC (Reckitt Benckiser Group plc)
TABLE 84 Key Information – collegium pharmaceutical
TABLE 85 Key Information – Orexo AB
TABLE 86 Key Information – Alkermes PLC
TABLE 87 Key Information – Titan Pharmaceuticals, Inc.
TABLE 88 Key Information – Camurus AB
TABLE 89 KEY INFORMATION – AstraZeneca PLC
TABLE 90 Key Information – Hikma Pharmaceuticals PLC
TABLE 91 Key information – Mallinckrodt PLC
TABLE 92 key information – Viatris, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 LAMEA Opioid Use Disorder (OUD) Market share by Drug Class, 2022
FIG 3 LAMEA Opioid Use Disorder (OUD) Market share by Drug Class, 2030
FIG 4 LAMEA Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2030, USD Million
FIG 5 LAMEA Opioid Use Disorder (OUD) Market share by Route of Administration, 2022
FIG 6 LAMEA Opioid Use Disorder (OUD) Market share by Route of Administration, 2030
FIG 7 LAMEA Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2030, USD Million
FIG 8 LAMEA Opioid Use Disorder (OUD) Market share by Distribution Channel, 2022
FIG 9 LAMEA Opioid Use Disorder (OUD) Market share by Distribution Channel, 2030
FIG 10 LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2030, USD Million
FIG 11 LAMEA Opioid Use Disorder (OUD) Market share by Country, 2022
FIG 12 LAMEA Opioid Use Disorder (OUD) Market share by Country, 2030
FIG 13 LAMEA Opioid Use Disorder (OUD) Market by Country, 2019 - 2030, USD Million